From major journals, first or last author from the Institute for Cancer Research
Hurley JH, Coyne AN, Miączyńska M, Stenmark H(2025) The expanding repertoire of ESCRT functions in cell biology and disease Nature(in press) DOI 10.1038/s41586-025-08950-y, PubMed 40562928
Thulin MH, Ramberg H, Nielsen HK, Grytli HH, Sivanesan S, Pandya AD, Seip K, Andressen KW, Linder A, Øijordsbakken M, Poutanen M, Katz B, Halvorsen B, Mælandsmo GM, Taskén KA(2025) Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis J Transl Med, 23(1), 672 DOI 10.1186/s12967-025-06644-7, PubMed 40528241
Singh R, Kyte JA(2025) STEAP1: a promising target in prostate cancer therapy Trends Cancer(in press) DOI 10.1016/j.trecan.2025.05.007, PubMed 40527692
Pagui ECK, Brant SB, Svendsen K, Frigessi A, Helland Å, Thoresen S, Jonasson C(2025) Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer Pharmacoepidemiol Drug Saf, 34(7), e70181 DOI 10.1002/pds.70181, PubMed 40552731
Hurley JH, Coyne AN, Miączyńska M, Stenmark H(2025) The expanding repertoire of ESCRT functions in cell biology and disease Nature(in press) DOI 10.1038/s41586-025-08950-y, PubMed 40562928
Kranjec C, Oftedal TF, Ovchinnikov KV, da Silva Duarte V, Hermansen S, Kaus-Drobek M, Sabała I, Porcellato D, Carlsen H, Kjos M(2025) An antibiotic-free antimicrobial combination of bacteriocins and a peptidoglycan hydrolase: in vitro and in vivo assessment of its efficacy Appl Environ Microbiol, e0243324(in press) DOI 10.1128/aem.02433-24, PubMed 40552825